Showing 1 - 15 of 15 results
ANSTO is a highly regulated organisation. Our governance system and processes provide critical guidance to effectively manage ANSTO’s activities. This section outlines the processes and systems that are in place to provide assurance to Government, our stakeholders and the community that we are working within our regulated and mandated requirements.
In January 2026, Mr Michael Quigley AM, ANSTO Board Chair, shared ANSTO's Statement of Intent with the Minister for Industry and Innovation, and Minister for Science.
Scandium 47, a therapeutic radioisotope and potential theranostic, has been produced for the first time at ANSTO. Theranostics are used to both diagnose and treat disease.
Michael Druce has been awarded a Public Service Medal in the Australia Day honours for his contribution to nuclear medicine production.
ANSTO provides access to specialised facilities and capabilities by application. Please ensure that you contact the relevant ANSTO scientist for advice before submitting a proposal.
The Government is safeguarding Australia’s sovereign capability to produce vital nuclear medicines by launching a $30 million project to design a new world-leading manufacturing facility to be built at Lucas Heights in Sydney.
ANSTO's reactor utilisation team has received an international award.
ANSTO is a unique national science organisation that began operating under its predecessor The Australian Atomic Energy Commission (AAEC) 70 years ago.
Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer is now available in Australia
Publications by ANSTO's National Deuteration Facility.